New Recruiting Trial: A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

WHY IT MATTERS

This trial offers patients with KRAS-mutated solid tumors access to a novel targeted therapy before it becomes widely available, potentially providing a treatment option for cancers that are often difficult to treat.

Researchers are testing a new experimental drug called KST-6051 in patients with advanced solid tumors (cancers that form in organs or tissues) that have a specific genetic mutation called KRAS. This is an early-stage study (Phase 1) that will test different doses of the drug to find the safest and most effective amount. The trial is now accepting patients and is expected to start in April 2026.

NCT ID: NCT07458347 Title: A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation Status: RECRUITING Phase: PHASE1 Sponsor: Kestrel Therapeutics, Inc. Start date: 2026-04-01 URL: https://clinicaltrials.gov/study/NCT07458347 Source: UniteRare clinical trials database

ASK YOUR DOCTOR

If you have an advanced solid tumor with a confirmed KRAS mutation, ask your oncologist whether you might be eligible for this trial and how to discuss enrollment options.